Developer docs
API playgroundTry for free, no card

Search company profiles

Ribocure Pharmaceuticals

Full company profile

uuid000276h

Namestring
Ribocure Pharmaceuticals
Legal namestring
Ribocure Pharmaceuticals AB
Websiteurl
ribocure.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Ribocure Pharmaceuticals AB is a clinical-stage Swedish biotech founded in May 2022 and headquartered at GoCo Clinic in Mölndal, Sweden. It is a wholly-owned subsidiary of Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938.HK, listed January 2026) and functions as the parent's European R&D and clinical hub for siRNA-based oligonucleotide therapeutics. The company builds on the proprietary RIBO-GalSTAR™ platform, a GalNAc-conjugated liver-targeting delivery system that enables selective siRNA uptake in hepatocytes for gene silencing across cardiovascular, renal, liver, and rare-disease indications. Its pipeline includes vortosiran (RBD4059), the world's first siRNA targeting coagulation Factor XI (Phase 2/2b in VTE, SPAF, and CAD); RBD1119 for coronary artery disease; RBD1016 for chronic hepatitis B and D (with EMA Orphan Drug Designation in HDV); RBD5044 for hypertriglyceridemia and mixed dyslipidemia; RBD7007 for complement-mediated diseases; and R0797070 for hypertension.

Ribocure operates a vertically integrated "bench-to-bedside" model, co-locating R&D, an in vitro human cell lab, and the in-house Ribocure Clinic Phase 2 clinical trial unit with functional imaging core lab capacity, allowing it to run proof-of-concept trials in cardiovascular, pulmonary, renal, and liver indications. It employs 11–50 staff drawn heavily from AstraZeneca's Cardiovascular, Renal and Metabolism organization, including the CEO, CMO, CBO, and most department heads.

The company's revenue model is B2B and pre-commercial: income is generated through out-licensing and co-development agreements with pharmaceutical partners, primarily via upfront payments, development and commercial milestone payments, and tiered royalties. Its two anchor deals are with Boehringer Ingelheim (January 2024, NASH/MASH collaboration valued at over $2 billion in upfront, milestones, and royalties) and Madrigal Pharmaceuticals (February 2026, exclusive worldwide license to six preclinical MASH siRNA programs, $60 million upfront with up to $4.4 billion in potential milestone payments plus royalties). AI is embedded into discovery workflows via partnerships with Insilico Medicine and Pheiron. Customer segments are large pharmaceutical companies (licensing/co-development partners) and clinical research sites/healthcare providers for trial execution.

Short descriptiontext

Ribocure Pharmaceuticals AB is a clinical-stage Swedish biotech and subsidiary of Suzhou Ribo Life Science (HKEX: 06938.HK) developing siRNA therapeutics using its proprietary RIBO-GalSTAR™ GalNAc liver-targeting platform. It out-licenses its cardiovascular, liver, and rare-disease pipeline to global pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersGothenburg, Sweden
HQ citystring
Gothenburg
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
siRNA therapeutics, oligonucleotide therapeutics, RNA interference drugs, gene silencing therapeutics, clinical stage biotech
Industry6 codes
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
RNA Therapeutics / siRNA Biopharmaceuticals
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Ribocure Clinic
Description

Specialized clinical trial unit within Ribocure Pharmaceuticals AB dedicated to Phase 2 proof-of-principle/concept trials with functional imaging core lab capacity, located at GoCo Clinic in Mölndal, Sweden.

ribocure.com
Core offering1 text field

Ribocure Pharmaceuticals AB is a clinical-stage biotech company developing siRNA (small interfering RNA)-based oligonucleotide therapeutics for cardiovascular, renal, liver, and rare diseases, powered by its proprietary RIBO-GalSTAR™ GalNAc liver-targeting delivery platform. The company advances multiple drug candidates (including vortosiran/RBD4059, RBD1119, RBD1016, RBD5044, RBD7007, and an AGT siRNA) through clinical development and monetizes them primarily through licensing and co-development agreements with large pharmaceutical partners. An in-house Phase 2 clinical trial unit (Ribocure Clinic) supports proof-of-concept studies with functional imaging core lab capacity.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Ribocure Pharmaceuticals is a clinical-stage biotech company developing cutting-edge siRNA (small interfering RNA) oligonucleotide therapeutics. The company's core portfolio includes multiple siRNA drug candidates targeting cardiovascular, metabolic, liver, and rare diseases. Key products include vortosiran (RBD4059) for FXI inhibition in thrombosis, RBD1119 for coronary artery disease, RBD1016 for hepatitis B/D, RBD5044 for hypertriglyceridemia, and RBD7007 for complement-mediated diseases. All programs leverage the proprietary RIBO-GalSTAR™ liver-targeting delivery platform. The company operates Ribocure Clinic, an in-house specialized Phase 2 clinical trial unit.

Product and service8 records
1vortosiran (RBD4059)
CategorysiRNA therapeutic (anti-thrombotic)
Description

World's first and most advanced GalNAc-conjugated siRNA drug targeting coagulation Factor XI (FXI). Achieves anti-thrombotic effects by suppressing FXI concentrations and inhibiting the intrinsic pathway of the coagulation cascade, offering durable antithrombotic protection with minimal bleeding risk. Being developed for multiple thrombotic indications including VTE, SPAF, and coronary artery disease.

2RBD1119
CategorysiRNA therapeutic (cardiovascular)
Description

siRNA-based therapeutic targeting coronary artery disease (CAD), addressing residual thrombotic risk in stable CAD patients that standard antiplatelet and anticoagulant therapies fail to adequately manage while seeking to reduce bleeding risks.

3RBD1016
CategorysiRNA therapeutic (infectious disease / rare disease)
Description

GalNAc-conjugated siRNA molecule targeting the X gene of hepatitis B virus. Inhibits all four HBV transcripts through RNA interference mechanism, reducing HBV DNA replication, cccDNA and HBsAg. Being developed for chronic hepatitis B infection and hepatitis D infection (HDV), the latter having received EMA Orphan Drug Designation in October 2025.

4RBD5044
CategorysiRNA therapeutic (metabolic disease)
Description

GalNAc-siRNA conjugate targeting Apolipoprotein CIII (ApoC3) for hypertriglyceridemia and mixed dyslipidemia. Achieves long-lasting and efficient reduction of plasma triglycerides and ApoB-containing lipoproteins.

5RBD7007
CategorysiRNA therapeutic (complement-mediated disease)
Description

GalNAc-conjugated siRNA targeting Complement Factor 5 (C5) mRNA in the liver. Being developed for complement-mediated diseases including Paroxysmal Nocturnal Hemoglobinuria (PNH), IgA nephropathy, and Myasthenia Gravis (MG).

6R0797070 (AGT siRNA)
CategorysiRNA therapeutic (cardiovascular / hypertension)
Description

GalNAc-siRNA molecule targeting liver angiotensinogen (AGT) for treatment of hypertension. Demonstrates sustained blood pressure reduction and improvement in left ventricular hypertrophy with best-in-class potential. Developed under the strategic collaboration with Boehringer Ingelheim.

7RIBO-GalSTAR™ Platform
CategoryProprietary drug delivery platform
Description

Proprietary liver-targeting siRNA delivery technology platform enabling selective uptake in hepatocytes for precise gene silencing. Powers Ribocure's siRNA therapeutic programs across cardiovascular, liver, and rare diseases via GalNAc conjugation.

8Ribocure Clinic
CategoryClinical trial services (Phase 2 / proof-of-concept)
Description

Specialized Phase 2 clinical trial unit within GoCo Clinic for conducting proof-of-principle and concept trials. Features functional imaging core lab capacity and specializes in cardiovascular, pulmonary, renal, and liver disease areas with advanced imaging and functional assessments. Enables in-house clinical execution for Ribocure's siRNA pipeline.

Partnership5 partners
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2026-05-01
Description

AI-powered drug discovery collaboration leveraging Insilico's AI platforms for target identification and drug design in Ribocure's siRNA pipeline development.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-02-01
Description

Licensing agreement for 6 preclinical siRNA programs targeting MASH (Metabolic dysfunction-Associated SteatoHepatitis). Deal includes $60 million upfront payment and up to $4.4 billion in potential milestone payments.

3Medtanken Group AB
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

Clinical trial collaboration with Medtanken Group AB for conducting clinical studies on siRNA therapeutic candidates in the Swedish healthcare system.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2024-09-01
Description

AI-assisted drug development partnership for optimizing siRNA therapeutic candidates using Pheiron's machine learning capabilities.

5Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Strategic partnership for NASH/MASH therapies development. This is a major collaboration exceeding $2 billion in potential deal value, representing Ribocure's flagship partnership for liver disease therapeutics.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The pioneer and dominant commercial player in RNAi therapeutics, with approved GalNAc-conjugated siRNA drugs (Givlauri, Oxlumo) directly competing with Ribocure's liver-targeting siRNA platform and pipeline targets including cardiovascular and metabolic diseases.

TypeDirect peer
Description

Clinical-stage RNAi therapeutics developer with multiple liver-targeted candidates (TRiM platform) in cardiometabolic and MASH indications that directly overlap with Ribocure's RIBO-GalSTAR platform strategy and target portfolio.

TypeDirect peer
Description

London-based clinical-stage siRNA company developing GalNAc-conjugated siRNA drugs for cardiovascular and hematological diseases (e.g., SLN360 targeting Lp(a)), competing head-to-head with Ribocure's RBD4059 and other GalNAc programs.

TypeDirect peer
Description

Clinical-stage oligonucleotide therapeutics company developing siRNA, ASO, and RNA editing programs. While Wave has a distinct PRISM platform, its cardiovascular and metabolic disease programs make it a direct comparable for RNA-targeted therapeutics in similar indications.

TypeBroad incumbent
Description

The leading antisense oligonucleotide (ASO) company with deep cardiovascular and metabolic disease expertise (e.g., Waylivra, Tegsedi, Tryngolza). Competes with Ribocure for pharma partnership attention and cardiovascular indication targets, though using a different oligonucleotide modality.

TypeEmerging player
Description

Clinical-stage HBV-focused biotech with GalNAc-conjugated siRNA (imdusiran) in chronic hepatitis B, directly comparable to Ribocure's RBD1016 program. Both target the same indication with RNAi-based approaches.

TypeBroad incumbent
Description

Acquired by Novo Nordisk for $3.3B in 2021, Dicerna developed GalXC RNAi platform technology with liver-targeting siRNAs. Now a wholly-owned subsidiary of Novo Nordisk, representing a fully integrated Big Pharma competitor in liver-targeted siRNA.

TypeEmerging player
Description

Clinical-stage RNA therapeutics company focused on rare diseases using Axiomer RNA editing technology. Adjacent modality (RNA editing vs siRNA) but targets similar rare disease indications and uses similar oligonucleotide delivery strategies.

TypeEmerging player
Description

Clinical-stage immunology company with siRNA-based HBV/HDV programs (VIR-2218) that directly overlap with Ribocure's RBD1016 hepatitis B/D development efforts. Strong Big Pharma partnerships (Gilead, Alnylam) make it a credible competitor.

TypeOthers
Description

AI-driven drug discovery company with Pharma.AI platform, partnered with Ribocure/Ribo (May 2026) for AI-assisted siRNA target identification and drug design. Not a direct competitor but a strategic enabler and ecosystem partner.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ribocure Pharmaceuticals

RNA Therapeutics / siRNA Biopharmaceuticalsribocure.com

Ribocure Pharmaceuticals AB is a clinical-stage Swedish biotech and subsidiary of Suzhou Ribo Life Science (HKEX: 06938.HK) developing siRNA therapeutics using its proprietary RIBO-GalSTAR™ GalNAc liver-targeting platform. It out-licenses its cardiovascular, liver, and rare-disease pipeline to global pharmaceutical partners.

What Ribocure Pharmaceuticals does

Ribocure Pharmaceuticals AB is a clinical-stage Swedish biotech founded in May 2022 and headquartered at GoCo Clinic in Mölndal, Sweden. It is a wholly-owned subsidiary of Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938.HK, listed January 2026) and functions as the parent's European R&D and clinical hub for siRNA-based oligonucleotide therapeutics. The company builds on the proprietary RIBO-GalSTAR™ platform, a GalNAc-conjugated liver-targeting delivery system that enables selective siRNA uptake in hepatocytes for gene silencing across cardiovascular, renal, liver, and rare-disease indications. Its pipeline includes vortosiran (RBD4059), the world's first siRNA targeting coagulation Factor XI (Phase 2/2b in VTE, SPAF, and CAD); RBD1119 for coronary artery disease; RBD1016 for chronic hepatitis B and D (with EMA Orphan Drug Designation in HDV); RBD5044 for hypertriglyceridemia and mixed dyslipidemia; RBD7007 for complement-mediated diseases; and R0797070 for hypertension.

Ribocure operates a vertically integrated "bench-to-bedside" model, co-locating R&D, an in vitro human cell lab, and the in-house Ribocure Clinic Phase 2 clinical trial unit with functional imaging core lab capacity, allowing it to run proof-of-concept trials in cardiovascular, pulmonary, renal, and liver indications. It employs 11–50 staff drawn heavily from AstraZeneca's Cardiovascular, Renal and Metabolism organization, including the CEO, CMO, CBO, and most department heads.

The company's revenue model is B2B and pre-commercial: income is generated through out-licensing and co-development agreements with pharmaceutical partners, primarily via upfront payments, development and commercial milestone payments, and tiered royalties. Its two anchor deals are with Boehringer Ingelheim (January 2024, NASH/MASH collaboration valued at over $2 billion in upfront, milestones, and royalties) and Madrigal Pharmaceuticals (February 2026, exclusive worldwide license to six preclinical MASH siRNA programs, $60 million upfront with up to $4.4 billion in potential milestone payments plus royalties). AI is embedded into discovery workflows via partnerships with Insilico Medicine and Pheiron. Customer segments are large pharmaceutical companies (licensing/co-development partners) and clinical research sites/healthcare providers for trial execution.

Ribocure Pharmaceuticals firmographics

Firmographics
Name
Ribocure Pharmaceuticals
Legal name
Ribocure Pharmaceuticals AB
Website
https://ribocure.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Short description
Ribocure Pharmaceuticals AB is a clinical-stage Swedish biotech and subsidiary of Suzhou Ribo Life Science (HKEX: 06938.HK) developing siRNA therapeutics using its proprietary RIBO-GalSTAR™ GalNAc liver-targeting platform. It out-licenses its cardiovascular, liver, and rare-disease pipeline to global pharmaceutical partners.
Ownership category
akta.pro rank

Ribocure Pharmaceuticals industry classification

Industry
Product category
RNA Therapeutics / siRNA Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • SiRNA therapeutics
  • Oligonucleotide therapeutics
  • RNA interference drugs
  • Gene silencing therapeutics
  • Clinical stage biotech

Where Ribocure Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Gothenburg
HQ country
Sweden
HQ region
Europe

Markets served

Ribocure Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Distribution channels3 records

Marketing channels4 records

Ribocure Pharmaceuticals product offering

Product offering

Core offering

Ribocure Pharmaceuticals AB is a clinical-stage biotech company developing siRNA (small interfering RNA)-based oligonucleotide therapeutics for cardiovascular, renal, liver, and rare diseases, powered by its proprietary RIBO-GalSTAR™ GalNAc liver-targeting delivery platform. The company advances multiple drug candidates (including vortosiran/RBD4059, RBD1119, RBD1016, RBD5044, RBD7007, and an AGT siRNA) through clinical development and monetizes them primarily through licensing and co-development agreements with large pharmaceutical partners. An in-house Phase 2 clinical trial unit (Ribocure Clinic) supports proof-of-concept studies with functional imaging core lab capacity.

Product overview

Ribocure Pharmaceuticals is a clinical-stage biotech company developing cutting-edge siRNA (small interfering RNA) oligonucleotide therapeutics. The company's core portfolio includes multiple siRNA drug candidates targeting cardiovascular, metabolic, liver, and rare diseases. Key products include vortosiran (RBD4059) for FXI inhibition in thrombosis, RBD1119 for coronary artery disease, RBD1016 for hepatitis B/D, RBD5044 for hypertriglyceridemia, and RBD7007 for complement-mediated diseases. All programs leverage the proprietary RIBO-GalSTAR™ liver-targeting delivery platform. The company operates Ribocure Clinic, an in-house specialized Phase 2 clinical trial unit.

Differentiator

Problem solved

Functional benefit

Brands

  • Ribocure Clinic: Specialized clinical trial unit within Ribocure Pharmaceuticals AB dedicated to Phase 2 proof-of-principle/concept trials with functional imaging core lab capacity, located at GoCo Clinic in Mölndal, Sweden.

Products and services

  • vortosiran (RBD4059) World's first and most advanced GalNAc-conjugated siRNA drug targeting coagulation Factor XI (FXI). Achieves anti-thrombotic effects by suppressing FXI concentrations and inhibiting the intrinsic pathway of the coagulation cascade, offering durable antithrombotic protection with minimal bleeding risk. Being developed for multiple thrombotic indications including VTE, SPAF, and coronary artery disease.
  • RBD1119 siRNA-based therapeutic targeting coronary artery disease (CAD), addressing residual thrombotic risk in stable CAD patients that standard antiplatelet and anticoagulant therapies fail to adequately manage while seeking to reduce bleeding risks.
  • RBD1016 GalNAc-conjugated siRNA molecule targeting the X gene of hepatitis B virus. Inhibits all four HBV transcripts through RNA interference mechanism, reducing HBV DNA replication, cccDNA and HBsAg. Being developed for chronic hepatitis B infection and hepatitis D infection (HDV), the latter having received EMA Orphan Drug Designation in October 2025.
  • RBD5044 GalNAc-siRNA conjugate targeting Apolipoprotein CIII (ApoC3) for hypertriglyceridemia and mixed dyslipidemia. Achieves long-lasting and efficient reduction of plasma triglycerides and ApoB-containing lipoproteins.
  • RBD7007 GalNAc-conjugated siRNA targeting Complement Factor 5 (C5) mRNA in the liver. Being developed for complement-mediated diseases including Paroxysmal Nocturnal Hemoglobinuria (PNH), IgA nephropathy, and Myasthenia Gravis (MG).
  • R0797070 (AGT siRNA) GalNAc-siRNA molecule targeting liver angiotensinogen (AGT) for treatment of hypertension. Demonstrates sustained blood pressure reduction and improvement in left ventricular hypertrophy with best-in-class potential. Developed under the strategic collaboration with Boehringer Ingelheim.
  • RIBO-GalSTAR™ Platform Proprietary liver-targeting siRNA delivery technology platform enabling selective uptake in hepatocytes for precise gene silencing. Powers Ribocure's siRNA therapeutic programs across cardiovascular, liver, and rare diseases via GalNAc conjugation.
  • Ribocure Clinic Specialized Phase 2 clinical trial unit within GoCo Clinic for conducting proof-of-principle and concept trials. Features functional imaging core lab capacity and specializes in cardiovascular, pulmonary, renal, and liver disease areas with advanced imaging and functional assessments. Enables in-house clinical execution for Ribocure's siRNA pipeline.

Companies that use Ribocure Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

Ribocure Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Ribocure Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered supporting and core.

  • Insilico MedicinesupportingTechnology or Integration · 1 May 2026AI-powered drug discovery collaboration leveraging Insilico's AI platforms for target identification and drug design in Ribocure's siRNA pipeline development.
  • Madrigal PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 1 February 2026Licensing agreement for 6 preclinical siRNA programs targeting MASH (Metabolic dysfunction-Associated SteatoHepatitis). Deal includes $60 million upfront payment and up to $4.4 billion in potential milestone payments.
  • Medtanken Group ABsupportingStrategic or Co-development Partner · 1 April 2025Clinical trial collaboration with Medtanken Group AB for conducting clinical studies on siRNA therapeutic candidates in the Swedish healthcare system.
  • PheironsupportingTechnology or Integration · 1 September 2024AI-assisted drug development partnership for optimizing siRNA therapeutic candidates using Pheiron's machine learning capabilities.
  • Boehringer IngelheimcoreStrategic or Co-development Partner · 1 January 2024Strategic partnership for NASH/MASH therapies development. This is a major collaboration exceeding $2 billion in potential deal value, representing Ribocure's flagship partnership for liver disease therapeutics.

Recent moves8 records

Expansion highlights6 records

Ribocure Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Alnylam Pharmaceuticals: The pioneer and dominant commercial player in RNAi therapeutics, with approved GalNAc-conjugated siRNA drugs (Givlauri, Oxlumo) directly competing with Ribocure's liver-targeting siRNA platform and pipeline targets including cardiovascular and metabolic diseases.
  • Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics developer with multiple liver-targeted candidates (TRiM platform) in cardiometabolic and MASH indications that directly overlap with Ribocure's RIBO-GalSTAR platform strategy and target portfolio.
  • Silence Therapeutics: London-based clinical-stage siRNA company developing GalNAc-conjugated siRNA drugs for cardiovascular and hematological diseases (e.g., SLN360 targeting Lp(a)), competing head-to-head with Ribocure's RBD4059 and other GalNAc programs.
  • Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company developing siRNA, ASO, and RNA editing programs. While Wave has a distinct PRISM platform, its cardiovascular and metabolic disease programs make it a direct comparable for RNA-targeted therapeutics in similar indications.

Broad incumbents

  • Ionis Pharmaceuticals: The leading antisense oligonucleotide (ASO) company with deep cardiovascular and metabolic disease expertise (e.g., Waylivra, Tegsedi, Tryngolza). Competes with Ribocure for pharma partnership attention and cardiovascular indication targets, though using a different oligonucleotide modality.
  • Dicerna Pharmaceuticals (Novo Nordisk): Acquired by Novo Nordisk for $3.3B in 2021, Dicerna developed GalXC RNAi platform technology with liver-targeting siRNAs. Now a wholly-owned subsidiary of Novo Nordisk, representing a fully integrated Big Pharma competitor in liver-targeted siRNA.

Emerging players

  • Arbutus Biopharma: Clinical-stage HBV-focused biotech with GalNAc-conjugated siRNA (imdusiran) in chronic hepatitis B, directly comparable to Ribocure's RBD1016 program. Both target the same indication with RNAi-based approaches.
  • ProQR Therapeutics: Clinical-stage RNA therapeutics company focused on rare diseases using Axiomer RNA editing technology. Adjacent modality (RNA editing vs siRNA) but targets similar rare disease indications and uses similar oligonucleotide delivery strategies.
  • Vir Biotechnology: Clinical-stage immunology company with siRNA-based HBV/HDV programs (VIR-2218) that directly overlap with Ribocure's RBD1016 hepatitis B/D development efforts. Strong Big Pharma partnerships (Gilead, Alnylam) make it a credible competitor.

Others

  • Insilico Medicine: AI-driven drug discovery company with Pharma.AI platform, partnered with Ribocure/Ribo (May 2026) for AI-assisted siRNA target identification and drug design. Not a direct competitor but a strategic enabler and ecosystem partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ribocure Pharmaceuticals social profiles

Digital presence

Ribocure Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ribocure Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles15 records

Ribocure Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ribocure Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ribocure Pharmaceuticals

What does Ribocure Pharmaceuticals do?

Ribocure Pharmaceuticals AB is a clinical-stage biotech company developing siRNA (small interfering RNA)-based oligonucleotide therapeutics for cardiovascular, renal, liver, and rare diseases, powered by its proprietary RIBO-GalSTAR™ GalNAc liver-targeting delivery platform. The company advances multiple drug candidates (including vortosiran/RBD4059, RBD1119, RBD1016, RBD5044, RBD7007, and an AGT siRNA) through clinical development and monetizes them primarily through licensing and co-development agreements with large pharmaceutical partners. An in-house Phase 2 clinical trial unit (Ribocure Clinic) supports proof-of-concept studies with functional imaging core lab capacity.

Is Ribocure Pharmaceuticals a public or private company?

Ribocure Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.

When was Ribocure Pharmaceuticals founded?

Ribocure Pharmaceuticals was founded in 2022. It employs 51 to 100 people.

Where is Ribocure Pharmaceuticals based?

Ribocure Pharmaceuticals is headquartered in Gothenburg, Sweden, in the Europe region.

Who are Ribocure Pharmaceuticals's main competitors?

Direct peers on record are Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics and Wave Life Sciences. Broad incumbents are Ionis Pharmaceuticals and Dicerna Pharmaceuticals (Novo Nordisk). Emerging players are Arbutus Biopharma, ProQR Therapeutics and Vir Biotechnology. Insilico Medicine is listed as an others.

Does Ribocure Pharmaceuticals have an API?

No public API is recorded for Ribocure Pharmaceuticals.

What industry is Ribocure Pharmaceuticals in?

Ribocure Pharmaceuticals's product category is RNA Therapeutics / siRNA Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MoomooHong Kong Stock Market Watch: Ribo Life Science-B (06938) rises over 6% on plan to acquire remaining stake in Ribocure Pharmaceuticals ABReBio Biotech-B shares rose over 6% to HK$53.9 on a plan to acquire the remaining stake in Ribocure Pharmaceuticals AB. The company agreed to acquire 49.71% of Ribocure, which focuses on siRNA-based therapies for cardiovascular and metabolic diseases.PRESSBEERibo soumet une demande dessai clinique européen pour une étude de phase I pour lARNsi RBD3133 ciblant lINHBE ...Middle EastSuzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals filed a phase I clinical trial application with the EU for RBD3133, an RNAi targeting INHBE. The trial is expected to begin in 2027, with the company seeking to advance the program.PRESSBEERibo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133 ...Middle EastSuzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals submitted a Phase I clinical trial application in the EU for RBD3133, an siRNA targeting INHBE. The announcement was made on Oct. 7, 2026, via PR Newswire.PR NewswireRibo veröffentlicht positive Daten aus der Phase-2a-Studie zu Vortosiran - weltweit erste klinische Daten zur siRNA-vermittelten FXI-Hemmung nach wiederholter Verabreichung bei Patienten mit koronarerSuzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced positive Phase 2a study results for Vortosiran (RBD4059), an siRNA therapy targeting Factor XI, in patients with chronic coronary heart disease on standard aspirin therapy. Patients in the high-dose group achieved a mean maximum FXI activity reduction of 92%, sustained over several months, with no treatment-related serious adverse events, severe bleeds, or clinically relevant non-severe bleeds reported. These results represent the world's first clinical proof-of-concept for siRNA-mediated FXI inhibition and support the initiation of the ORBIT-XI Phase 2b program to advance the candidate toward Phase 3 development.PR Newswire APACWorld's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery DiseaseSuzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced positive Phase 2a study results for vortosiran (RBD4059), an siRNA therapy targeting Factor XI, in patients with chronic coronary artery disease receiving standard aspirin therapy. The randomized, double-blind, placebo-controlled study conducted in Europe demonstrated that patients on the 400mg maintenance dose achieved 92% mean maximum reduction in FXI activity sustained for several months, with no treatment-related serious adverse events or bleeding events observed. The companies have initiated the ORBIT-XI program including Phase 2b trials to support progression into Phase 3 development across multiple indications.PR NewswireRibo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery DiseaseSuzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced positive Phase 2a trial results for vortosiran (RBD4059), an siRNA therapy targeting coagulation Factor XI, in patients with chronic coronary artery disease receiving standard aspirin therapy. Patients on the high-dose regimen achieved a mean maximum reduction in FXI activity of 92%, sustained for several months, with no treatment-related serious adverse events or major bleeding events observed. The findings represent the world's first clinical proof-of-concept for siRNA-mediated FXI suppression in CAD patients, supporting vortosiran's potential as a differentiated long-acting antithrombotic therapy, and the company has initiated the ORBIT-XI Phase 2b program for further development.PR NewswireRibo und Madrigal erreichen ersten wichtigen Meilenstein bei der Weiterentwicklung neuartiger siRNA-Therapien für MASHSuzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB, in partnership with Madrigal Pharmaceuticals, have successfully achieved the first drug candidate nomination milestone in their siRNA collaboration for metabolic-associated steatohepatitis (MASH). Following this milestone, the companies will immediately initiate IND-enabling studies to support planned clinical trials, combining Ribo's siRNA drug research and delivery technology expertise with Madrigal's established clinical leadership in MASH. The collaboration aims to address significant unmet medical need by developing novel liver-targeted RNA therapeutics for patients suffering from MASH worldwide.PR NewswireRibo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASHSuzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB, in collaboration with Madrigal Pharmaceuticals, have achieved the first candidate drug nomination milestone in their siRNA alliance for Metabolic dysfunction-Associated SteatoHepatitis (MASH). The milestone triggers immediate initiation of preclinical studies to support Investigational New Drug (IND) applications for planned clinical trials. The collaboration encompasses multiple preclinical assets targeting liver diseases with significant unmet medical needs, combining Madrigal's clinical leadership in MASH with Ribo's siRNA drug discovery and delivery technology capabilities.PR NewswireRibo et Madrigal franchissent une première étape majeure dans le développement de nouvelles thérapies à base d'ARNsi pour la stéatohépatite associée à un dysfonctionnement métabolique (MASH)Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB, in collaboration with Madrigal Pharmaceuticals, have successfully achieved the first key drug candidate designation milestone in their siRNA partnership focused on Metabolic dysfunction-Associated SteatoHepatitis (MASH). The collaboration leverages Madrigal's clinical leadership and expertise in MASH alongside Ribo's global siRNA drug discovery and delivery capabilities to advance multiple preclinical projects targeting liver diseases. The companies have committed to accelerating the development of the siRNA candidate toward clinical trials.MorningstarRibo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASHRibo and Madrigal announced the first candidate drug nomination milestone in their siRNA partnership for MASH, with IND-enabling studies to follow. The collaboration covers multiple preclinical assets and aims to accelerate development of novel siRNA therapies for liver disease.